CN107667107B - 乙炔基衍生物 - Google Patents

乙炔基衍生物 Download PDF

Info

Publication number
CN107667107B
CN107667107B CN201680029481.6A CN201680029481A CN107667107B CN 107667107 B CN107667107 B CN 107667107B CN 201680029481 A CN201680029481 A CN 201680029481A CN 107667107 B CN107667107 B CN 107667107B
Authority
CN
China
Prior art keywords
methyl
phenyl
phenylethynyl
trione
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680029481.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107667107A (zh
Inventor
乔治·耶施克
菲奥·奥哈拉
让-马克·普朗谢
安东尼奥·里奇
丹尼尔·吕厄
埃里克·维埃拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107667107A publication Critical patent/CN107667107A/zh
Application granted granted Critical
Publication of CN107667107B publication Critical patent/CN107667107B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680029481.6A 2015-08-03 2016-08-02 乙炔基衍生物 Expired - Fee Related CN107667107B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179550 2015-08-03
EP15179550.7 2015-08-03
PCT/EP2016/068359 WO2017021384A1 (en) 2015-08-03 2016-08-02 Ethynyl derivatives

Publications (2)

Publication Number Publication Date
CN107667107A CN107667107A (zh) 2018-02-06
CN107667107B true CN107667107B (zh) 2021-05-18

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029481.6A Expired - Fee Related CN107667107B (zh) 2015-08-03 2016-08-02 乙炔基衍生物

Country Status (20)

Country Link
US (1) US10011607B2 (enExample)
EP (1) EP3331882B1 (enExample)
JP (1) JP6975511B2 (enExample)
KR (1) KR20180030857A (enExample)
CN (1) CN107667107B (enExample)
AR (1) AR105556A1 (enExample)
AU (1) AU2016302696B2 (enExample)
BR (1) BR112017023951A2 (enExample)
CA (1) CA2983908A1 (enExample)
CL (1) CL2018000278A1 (enExample)
CO (1) CO2017011010A2 (enExample)
IL (1) IL255103B (enExample)
MX (1) MX2018001486A (enExample)
PE (1) PE20180357A1 (enExample)
PH (1) PH12018500247A1 (enExample)
RU (1) RU2722014C9 (enExample)
TW (1) TWI621619B (enExample)
UA (1) UA120888C2 (enExample)
WO (1) WO2017021384A1 (enExample)
ZA (1) ZA201707015B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
AU2016302144B2 (en) 2015-08-03 2020-10-08 Bristol-Myers Squibb Company Heterocyclic compounds useful as modulators of TNF alpha
PT3331863T (pt) 2015-08-03 2020-05-22 Glenmark Pharmaceuticals Sa Novos compostos como moduladores de ror gama
TW202039425A (zh) 2018-12-21 2020-11-01 德商馬克專利公司 雙取代炔類衍生物、包含其之藥物組成及組、及用於製備其之製程

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044075A1 (en) * 2013-09-25 2015-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
WO2015104271A1 (en) * 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
WO2015128307A1 (en) * 2014-02-25 2015-09-03 F. Hoffmann-La Roche Ag Ethynyl derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010314891A1 (en) * 2009-11-06 2012-06-07 Vanderbilt University Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
EP2702050B1 (en) * 2011-04-26 2016-05-18 F.Hoffmann-La Roche Ag Pyrazolidin-3-one derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015044075A1 (en) * 2013-09-25 2015-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives
WO2015104271A1 (en) * 2014-01-10 2015-07-16 F. Hoffmann-La Roche Ag Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
WO2015128307A1 (en) * 2014-02-25 2015-09-03 F. Hoffmann-La Roche Ag Ethynyl derivatives

Also Published As

Publication number Publication date
JP2018522037A (ja) 2018-08-09
CA2983908A1 (en) 2017-02-09
KR20180030857A (ko) 2018-03-26
HK1246790A1 (zh) 2018-09-14
TW201718589A (zh) 2017-06-01
ZA201707015B (en) 2018-11-28
WO2017021384A1 (en) 2017-02-09
BR112017023951A2 (pt) 2018-07-24
PE20180357A1 (es) 2018-02-21
RU2722014C9 (ru) 2020-10-22
CN107667107A (zh) 2018-02-06
UA120888C2 (uk) 2020-02-25
IL255103A0 (en) 2017-12-31
MX2018001486A (es) 2018-03-15
EP3331882A1 (en) 2018-06-13
TWI621619B (zh) 2018-04-21
CL2018000278A1 (es) 2018-07-06
AU2016302696A1 (en) 2017-11-02
JP6975511B2 (ja) 2021-12-01
RU2722014C2 (ru) 2020-05-26
AR105556A1 (es) 2017-10-18
US10011607B2 (en) 2018-07-03
AU2016302696B2 (en) 2020-05-07
CO2017011010A2 (es) 2018-02-09
RU2018105872A3 (enExample) 2019-12-26
IL255103B (en) 2020-01-30
PH12018500247A1 (en) 2018-08-13
US20180127429A1 (en) 2018-05-10
EP3331882B1 (en) 2020-04-29
RU2018105872A (ru) 2019-09-05

Similar Documents

Publication Publication Date Title
US10421744B2 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
EP3889134B1 (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP2570411A1 (en) Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity
TWI448465B (zh) 乙炔基衍生物
CN107667107B (zh) 乙炔基衍生物
CN105579447B (zh) 乙炔基衍生物
JP6286577B2 (ja) エチニル誘導体
TWI605042B (zh) 乙炔基衍生物
TWI473799B (zh) 芳基乙炔基衍生物
CN111032659A (zh) 用于治疗诸如帕金森病的疾病的咪唑并[1，2-a]咪唑-2-酮衍生物
HK1246790B (zh) 乙炔基衍生物
HK1241881A1 (en) 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4
HK40051501A (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
HK40051501B (en) Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
HK1241881B (zh) 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2，4-二酮衍生物
HK1220200B (zh) 乙炔基衍生物
HK1226404A1 (en) Ethynyl derivatives
HK1226404B (zh) 乙炔基衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246790

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210518

CF01 Termination of patent right due to non-payment of annual fee